Australian antiviral developer Island Pharmaceuticals (ASX:ILA) has been granted US Patent Number 12,508,266 by the US Patent and Trademark Office for the use of Galidesivir in the treatment of filoviridae viruses, including Ebola and Marburg.
The patent, which provides protection through 14 October 2031, covers a broad range of claims for administering therapeutically effective doses of Galidesivir to combat infections caused by this family of single-stranded negative-sense RNA viruses.
The approval strengthens Island’s growing intellectual property portfolio, acquired as part of its Galidesivir program, and aligns with the company's clinical development strategy, including the FDA’s November 2025 confirmation of an approval pathway for Marburg treatment under the Animal Rule.